DCF Advisers’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

DCF Advisers’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-178,500	Closed	-$76.8K	–	106
2023 Q3	$76.8K	Sell	178,500 -125,105	-41%	-$120K	0.04%	92
2023 Q2	$386K	Sell	303,605 -79,543	-21%	-$121K	0.2%	67
2023 Q1	$536K	Buy	383,148 +57,323	+18%	+$137K	0.33%	47
2022 Q4	$1.22M	Sell	325,825 -143,358	-31%	-$522K	0.83%	31
2022 Q3	$2.29M	Buy	469,183 +30,617	+7%	+$234K	1.48%	24
2022 Q2	$4.09M	Buy	438,566 +71,508	+19%	+$522K	2.43%	11
2022 Q1	$2.34M	Buy	367,058 +111,031	+43%	+$839K	1.02%	28
2021 Q4	$2.21M	Buy	256,027 +106,027	+71%	+$1.06M	0.9%	32
2021 Q3	$1.83M	Buy	+150,000	New	+$2.18M	0.81%	34

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

DCF Advisers's IMPL Position: Q4 2023 in Review

DCF Advisers sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 178,500 shares — an estimated $76.8K sold.

DCF Advisers first reported a position in IMPL in Q3 2021 and held it in 9 quarters. The position peaked at $4.09M in Q2 2022. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

DCF Advisers reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
DCF Advisers sold 178,500 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $76.8K.
DCF Advisers first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 9 quarters.
DCF Advisers's Impel Pharmaceuticals Inc. Common Stock position peaked at $4.09M in Q2 2022.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on DCF Advisers's 13F filing for Q4 2023, filed 13 Feb 2024.